{"brief_title": "A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer", "brief_summary": "This study will assess the efficacy and safety of continuous oral Xeloda administration in combination with intravenous irinotecan as a first-line treatment in patients with advanced and/or metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months and the target sample size is <100 individuals.", "condition": "Colorectal Cancer", "intervention_type": "Drug", "intervention_name": "capecitabine [Xeloda]", "description": "1000mg po bid", "arm_group_label": "1", "criteria": "Inclusion Criteria: - adult patients >=18 years of age; - locally advanced and/or metastatic colorectal cancer; - >=1 target lesion. Exclusion Criteria: - previous treatment with Xeloda or irinotecan; - previous systemic therapy for metastatic disease; - progressive disease during previous adjuvant therapy or within 6 months of completion.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00048126.xml"}